默克300亿天价收购传闻背后的RAS革命：Revolution Medicines的“三元复合物”平台，揭秘“分子胶水”技术如何破解癌症“死亡之星”KRAS

医道社创新药新...

01/11

医道社：传承和发展民间中医来源：海外网站作者：医道社整理版权归原作者所有，如有违规、侵权请联系我们删除！关注不迷路，更多创新药前沿资讯大家好，我是你们的创新药专业博主老汤。作为临床医生和药品研发人员，你们每天面对的肿瘤患者中，RAS突变型癌症占比不小吧？那些KRAS G12C、G12D突变的肺癌、胰腺癌、结直肠癌，总让人觉得棘手——传统靶向药效果有限，耐药来得快。今天，我们来聊聊...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602958593"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602958593\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602958593?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-11 20:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2602958593","market":"us","top_or_hot":-1,"title":"默克300亿天价收购传闻背后的RAS革命：Revolution Medicines的“三元复合物”平台，揭秘“分子胶水”技术如何破解癌症“死亡之星”KRAS","media":"医道社创新药新...","content":"<div>\n<p>医道社：传承和发展民间中医来源：海外网站 作者：医道社整理版权归原作者所有，如有违规、侵权请联系我们删除！关注不迷路，更多创新药前沿资讯大家好，我是你们的创新药专业博主老汤。作为临床医生和药品研发人员，你们每天面对的肿瘤患者中，RAS突变型癌症占比不小吧？那些KRAS G12C、G12D突变的肺癌、胰腺癌、结直肠癌，总让人觉得棘手——传统靶向药效果有限，耐药来得快。今天，我们来聊聊...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111202339a70db7d8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默克300亿天价收购传闻背后的RAS革命：Revolution Medicines的“三元复合物”平台，揭秘“分子胶水”技术如何破解癌症“死亡之星”KRAS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默克300亿天价收购传闻背后的RAS革命：Revolution Medicines的“三元复合物”平台，揭秘“分子胶水”技术如何破解癌症“死亡之星”KRAS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 20:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111202339a70db7d8&s=b><strong>医道社创新药新...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>医道社：传承和发展民间中医来源：海外网站 作者：医道社整理版权归原作者所有，如有违规、侵权请联系我们删除！关注不迷路，更多创新药前沿资讯大家好，我是你们的创新药专业博主老汤。作为临床医生和药品研发人员，你们每天面对的肿瘤患者中，RAS突变型癌症占比不小吧？那些KRAS G12C、G12D突变的肺癌、胰腺癌、结直肠癌，总让人觉得棘手——传统靶向药效果有限，耐药来得快。今天，我们来聊聊...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111202339a70db7d8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0861579265.USD","symbol_name":"联博低波幅策略股票基金A","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111202339a70db7d8&s=b","article_id":"2602958593","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111202339a70db7d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602958593","pubTimestamp":1768133210,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"今天，我们来聊聊Revolution Medicines，这家被默克传闻以280-320亿美元天价洽购的公司。更巧的是，就在传闻高峰，FDA授予RVMD的zoldonrasib突破性疗法认定，用于KRAS G12D突变型晚期NSCLC。RVMD掌握的“三元复合物”平台，能系统靶向RAS，覆盖30%癌症患者。在NSCLC模型中，sotorasib用后，肿瘤复发多因ON状态上调。Nature Reviews Drug Discovery称，这是“RAS靶向的范式转变”。FDA BTD用于KRAS G12C NSCLC二线。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0861579265.USD":"联博低波幅策略股票基金A","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","RVMD":"Revolution Medicines, Inc.","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","MRK":"默沙东","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","BK4007":"制药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","BK4534":"瑞士信贷持仓","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4139":"生物科技","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4516":"特朗普概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","BK4559":"巴菲特持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD"},"translate_title":"The RAS revolution behind Merck's 30 billion sky-high acquisition rumors: Revolution Medicines' \"ternary complex\" platform reveals how \"molecular glue\" technology cracks cancer \"death star\" KRAS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1.98,"MRK":1.87},"content_text":"医道社：传承和发展民间中医来源：海外网站 作者：医道社整理版权归原作者所有，如有违规、侵权请联系我们删除！关注不迷路，更多创新药前沿资讯大家好，我是你们的创新药专业博主老汤。作为临床医生和药品研发人员，你们每天面对的肿瘤患者中，RAS突变型癌症占比不小吧？那些KRAS G12C、G12D突变的肺癌、胰腺癌、结直肠癌，总让人觉得棘手——传统靶向药效果有限，耐药来得快。今天，我们来聊聊Revolution Medicines（纳斯达克：RVMD），这家被默克传闻以280-320亿美元天价洽购的公司。它不是靠风口起飞，而是靠一个硬核平台：三元复合物抑制剂，直接瞄准RAS的活性状态（RAS(ON)）。这事儿最近闹得沸沸扬扬，股价单日暴涨10.7%，市值逼近200亿，但核心是科学——它怎么破解了40年“不可成药”的魔咒？基于公开的Science论文、FDA公告和临床数据，我来一步步拆解，让大家从机制到管线都看明白。走起！第一章：一周风云突变，RVMD为何成巨头“香饽饽”？最近的生物医药圈，RVMD绝对是焦点。2026年1月10日，《金融时报》爆出默克正以280-320亿美元的价格洽购这家公司，股价应声拉到118.64美元，市值直奔200亿大关。如果成交，这将是近三年最大医药收购案，堪比辉瑞430亿买Seagen。之前还有AbbVie的“乌龙”传闻，股价过山车般起伏，但默克的绯闻更靠谱——路透社和瑞穗证券都跟进报道，强调这是默克为Keytruda专利到期（2028年）后的布局。更巧的是，就在传闻高峰，FDA授予RVMD的zoldonrasib（RMC-9805）突破性疗法认定（BTD），用于KRAS G12D突变型晚期NSCLC。这已经是RVMD第三款获BTD的RAS抑制剂了！BTD意味着FDA加速审评，临床沟通更顺畅，尤其对G12D这种无靶向药的蓝海适应症，含金量高。为什么默克这么疯狂？不是简单并购故事。RVMD掌握的“三元复合物”平台，能系统靶向RAS(ON)，覆盖30%癌症患者。瑞穗预测，到2035年，其管线风险调整销售额超100亿。JPM医疗大会上，RVMD高管将演讲，估计会披露更多细节。作为医生和研发者，你们知道：这不只商业，更是技术范式切换，从“药物1.0/2.0”到“3.0”——直接锁死活性RAS，而不是等它“关机”。第二章：RAS，癌症的“最大难啃骨头”——40年失败史与痛点先说说RAS，为什么它这么难搞？RAS基因突变是人类癌症中最常见的驱动因素，占约30%实体瘤：NSCLC中25-30%，结直肠癌40%，胰腺癌90%（American Cancer Society 2023）。KRAS G12C、G12D、G12V、Q61H等热点突变，像个“死亡之星”，卡在ON状态（GTP结合），持续激活下游ERK、AKT、PI3K通路，导致肿瘤疯狂生长。过去40年，RAS被叫“undruggable”——蛋白表面光滑，没结合口袋，小分子抓不住。直到2019-2021年，安进的sotorasib（Lumakras）和Mirati/BMS的adagrasib获批，针对KRAS G12C的OFF状态（GDP结合）。临床数据呢？ORR 37-45%，mPFS 6-8个月（NEJM 2021-2023）。但局限明显：·只打OFF状态：癌细胞通过核苷酸交换或RTK（如EGFR/MET）刺激，快速切换到ON状态，绕过抑制。生长因子一刺激，药效就打折。·耐药快：二次突变（如R68S、H95D、Y96C）常见，耐药率50%以上（Cancer Discovery 2023）。在NSCLC模型中，sotorasib用后，肿瘤复发多因ON状态上调。·单一靶点：只盖G12C，忽略G12D（胰腺癌主凶）等更广谱突变。现有方案有限，化疗/免疫疗法效果差，患者需求迫切。行业呼声：需要ON状态抑制剂！RVMD的平台，正好填这个坑。它不绕弯，直接用“分子胶水”重塑RAS表面，创造新结合界面。Nature Reviews Drug Discovery（2023）称，这是“RAS靶向的范式转变”。第三章：核心黑科技——三元复合物平台，“分子胶水”如何降维打击？RVMD的杀手锏是Tri-Complex Inhibitor Platform，灵感从自然界来：雷帕霉素/FK506用免疫亲和素（如CYPA）形成复合物调控靶点。RVMD工程师化它，针对RAS(ON)。机制拆解（通俗说，像雇“保镖”抓贼）：1.小分子“胶水”入门：药物（如基于sanglifehrin A的化合物）高亲和绑定CYPA（细胞内常见蛋白，无害）。2.重塑表面：胶水改造CYPA，创造新疏水/电荷界面——专为RAS(ON)设计。晶体结构（1.4-1.53Å分辨率，Science 2023）显示，吲哚环π-π堆积Switch II，N71/K151氢键E31。3.三元锁定：CYPA-药物复合物共价绑RAS G12C的C12（或其它突变位点），形成稳定三元体。结果？RAS无法与下游效应蛋白（CRAF、PI3K、SOS1、RALGDS）结合，信号全断。这不是PROTAC（降解蛋白），而是功能封堵（functional blockade）。优势震撼：·ON状态直击：不受核苷酸交换影响。5分钟内完全修饰KRAS G12C（图S9D，Science 2023），CRAF解离速度是adagrasib的10倍（图3B）。RTK刺激下，ERK抑制90%以上 vs. 第一代50%（图3C）。·选择性爆表：RMC-6291对G12C IC50=0.11nM，选择性13,500倍（蛋白组分析，补充S11）。对非G12C细胞差异>10^3-10^4倍，脱靶低。·无视耐药：不接触Y96/R68等位点，饱和突变筛选确认（图S7D）。在耐药模型中，仍有效。·平台可扩展：调整胶水结构，定制不同突变。临床前：3D细胞panel中，KRAS G12C模型IC50中位0.1nM。小鼠PDX中，每日口服导致76% NSCLC模型肿瘤消退，40%结直肠癌（图4D）；TUNEL凋亡率升5倍（图S12）。Science 2023（doi:10.1126/science.add3251）是铁证：从RMC-4998优化到临床候选，结构&生化数据全覆盖。相比第一代，这像从“狙击OFF”到“围剿ON”——疗效更深、更持久。第四章：管线军团——从单一到全谱，RVMD的RAS“宇宙”RVMD不玩单打独斗，管线系统覆盖RAS 90%突变。全是ON抑制剂，I/II期为主（ClinicalTrials.gov NCT05379985、NCT05462717）。·RMC-6236（Daraxonrasib，RAS多选ON抑制剂）：广谱导弹，盖G12X/G13X/Q61X。I/II期（n=78，RAS依赖实体瘤），单药ORR 35%，联合osimertinib ORR 60%（ASCO 2023）。FDA BTD用于KRAS G12C NSCLC二线。胰腺癌/结直肠癌中，观察到临床缓解+长疾病控制。峰值销售潜力50亿+（瑞穗2023）。·RMC-6291（Elironrasib，KRAS G12C ON）：同类最佳挑战者。临床前：NSCLC PDX消退76%（n=25）。I期耐受好，推荐剂量200mg QD口服。与PD-1联用，瞄准耐药/复发市场。G12C二次突变下，仍保留活性；EGF刺激不反弹。·RMC-9805（Zoldonrasib，KRAS G12D ON）：重磅！首个G12D ON候选，BTD用于既往PD1+铂类失败的晚期NSCLC（G12D占4% NSCLC，胰腺/CRC更高）。I期RMC-9805-001：单药“鼓舞人心的抗肿瘤活性”+良好安全性。蓝海——无批准G12D药，加速批准可能大。·其他：RMC-5127（G12V ON，临床前，结直肠癌常见）；RMC-0708（Q61H）；RMC-8839（G13C）。这些复用平台，风险低。整体：从“pipeline-in-a-drug”到RAS全覆盖，像HER2/EGFR宇宙。招募超500患者，多中心，美欧亚。Sanofi合作（SHP2，里程碑>10亿）加持。第五章：临床&市场双轮驱动——为什么RVMD的潜力超100亿？临床优势直观：ON靶向避开第一代痛点。模型中，肿瘤消退快（28天完全退，p<0.001，n=8）；联合潜力大，与PD-1/MEK联用，疗效翻倍。安全性：口服，每日剂量耐受好，无严重脱靶。市场：RAS市场2030年150亿（Grand View 2023）。RVMD先发：唯一ON平台，管线丰富。G12D BTD插“监管旗”，G12C抢耐药份额。联合Keytruda：KRAS肿瘤PD1低效，ON抑制+免疫可开新适应症。默克视角：Keytruda悬崖需填，RAS+免疫协同完美。平台扩展到MYC/TP53等undruggable靶点。交易灵活：不止管线，还有技术护城河（200+专利）。第六章：公司实力&行业新范式——平台型估值逻辑RVMD（2014成立，加州，300+员工）：团队顶尖，结构生物+计算化学强（晶体1.4Å）。CEO Mark Goldsmith（前Genentech）跨“Nature到IND”。专注RAS，资源高效。现金12亿（Q3 2023），撑到2026。行业趋势：平台公司溢价高。可扩展研发、低风险、多价值驱动。像Seagen ADC（430亿），RVMD的RAS平台更核心。Stifel预测：RMC-6236获批，市值翻三倍（Barron's 2023）。Bloomberg/Fierce Biotech：RVMD超Mirati/Amgen，因ON解决耐药。风险：III期不确定，竞争（BMS Mirati）。但数据硬：ORR35-60%，选择性万倍。结语：RVMD，不止收购，是RAS时代的曙光老汤的深度思考：RVMD震撼在于，它用工程化三元复合物，工业化攻克RAS(ON)。对医生：新选项救G12D患者；对研发：样板路径，从结构到临床。作为见证者，期待ASCO/ESMO数据、JPM演讲。RAS未来？ON抑制+联合，或重塑指南。欢迎医生/研发同行留言：你怎么看三元复合物在临床的潜力？点赞+转发，一起聊创新药！（数据实时跟进公众号。）参考文献：1.Revolution Medicines. Science. 2023; doi:10.1126/science.add3251.2.FDA Breakthrough Therapy Designation. RevMed Announcement, 2023.3.ClinicalTrials.gov: NCT05379985 (RMC-6236); NCT05462717.4.ASCO 2023 Abstracts; NEJM 2021-2023 Trials.5.Mizuho Securities RAS Market Report, 2023.6.Nature Reviews Drug Discovery: \"Targeting RAS(ON)\", 2023.7.Cancer Discovery, 2023; American Cancer Society 2023.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}